Old and new basal insulin formulations: understanding pharmacodynamics is still relevant in clinical practice
出版年份 2014 全文链接
标题
Old and new basal insulin formulations: understanding pharmacodynamics is still relevant in clinical practice
作者
关键词
-
出版物
DIABETES OBESITY & METABOLISM
Volume 16, Issue 8, Pages 695-706
出版商
Wiley
发表日期
2014-01-09
DOI
10.1111/dom.12256
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation
- (2014) N Waugh et al. HEALTH TECHNOLOGY ASSESSMENT
- A comparison of the pharmacodynamic profiles of insulin detemir and insulin glargine: A single dose clamp study in people with type 2 diabetes
- (2013) S.D. Luzio et al. DIABETES & METABOLISM
- The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily: A 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes
- (2013) L. Meneghini et al. DIABETES CARE
- Newer insulin analogs: advances in basal insulin replacement
- (2013) Bernard Zinman DIABETES OBESITY & METABOLISM
- Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes
- (2013) L. Meneghini et al. DIABETES OBESITY & METABOLISM
- Pharmacodynamics of the long-acting insulin analogues detemir and glargine following single-doses and under steady-state conditions in patients with type 1 diabetes
- (2013) G. Koehler et al. DIABETES OBESITY & METABOLISM
- Variability of glucose-lowering effect as a limiting factor in optimizing basal insulin therapy: a review
- (2013) J. Vora et al. DIABETES OBESITY & METABOLISM
- Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus
- (2013) V. P. Sinha et al. DIABETES OBESITY & METABOLISM
- The Future of Basal Insulin
- (2013) Viral N. Shah et al. Diabetes Technology & Therapeutics
- Basal insulin analogues in the management of diabetes mellitus: what progress have we made?
- (2013) David R. Owens et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Hypoglycemia: Still the Limiting Factor in the Glycemic Management of Diabetes
- (2013) Philip Cryer Endocrine Practice
- Efficacy and Safety of Insulin Degludec in a Flexible Dosing Regimen vs Insulin Glargine in Patients With Type 1 Diabetes (BEGIN: Flex T1): A 26-Week Randomized, Treat-to-Target Trial With a 26-Week Extension
- (2013) Chantal Mathieu et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- European Medicines Agency must take account of cardiovascular harm associated with degludec insulin
- (2013) T. A. Schmidt et al. BMJ-British Medical Journal
- Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes: A randomized, crossover study
- (2012) J. Rosenstock et al. DIABETES CARE
- A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin-Treated Patients With Type 2 Diabetes
- (2012) R. M. Bergenstal et al. DIABETES CARE
- Insulin Degludec/Insulin Aspart Administered Once Daily at Any Meal, With Insulin Aspart at Other Meals Versus a Standard Basal-Bolus Regimen in Patients With Type 1 Diabetes: A 26-week, phase 3, randomized, open-label, treat-to-target trial
- (2012) I. B. Hirsch et al. DIABETES CARE
- Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes: A 1-year, randomized, treat-to-target trial (BEGIN Once Long)
- (2012) B. Zinman et al. DIABETES CARE
- Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2012) S. E. Inzucchi et al. DIABETES CARE
- Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials
- (2012) R. E. Ratner et al. DIABETES OBESITY & METABOLISM
- A direct comparison of the pharmacodynamic properties of insulin detemir and neutral protamine lispro insulin in patients with type 1 diabetes
- (2012) S. Korsatko et al. DIABETES OBESITY & METABOLISM
- Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes
- (2012) T. Heise et al. DIABETES OBESITY & METABOLISM
- Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes
- (2012) T. Heise et al. DIABETES OBESITY & METABOLISM
- Insulin resistance in multiple tissues in patients with type 1 diabetes mellitus on long-term continuous subcutaneous insulin infusion therapy
- (2012) Esther Donga et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Features of Hepatic and Skeletal Muscle Insulin Resistance Unique to Type 1 Diabetes
- (2012) Bryan C. Bergman et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial
- (2012) Alan J Garber et al. LANCET
- Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial
- (2012) Simon Heller et al. LANCET
- Pharmacokinetics and Pharmacodynamics of Therapeutic Doses of Basal Insulins NPH, Glargine, and Detemir After 1 Week of Daily Administration at Bedtime in Type 2 Diabetic Subjects: A randomized cross-over study
- (2011) P. Lucidi et al. DIABETES CARE
- Revisiting the efficacy of long-acting insulin analogues on adults with type 1 diabetes using mixed-treatment comparisons
- (2011) Andréia Cristina Conegero Sanches et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030
- (2011) David R. Whiting et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Cost–effectiveness of insulin detemir: a systematic review
- (2011) Dong-Churl Suh et al. Expert Review of Pharmacoeconomics & Outcomes Research
- A 24-Week, Randomized, Treat-to-Target Trial Comparing Initiation of Insulin Glargine Once-Daily With Insulin Detemir Twice-Daily in Patients With Type 2 Diabetes Inadequately Controlled on Oral Glucose-Lowering Drugs
- (2010) S. G. Swinnen et al. DIABETES CARE
- Dose-Response Effects of Insulin Glargine in Type 2 Diabetes
- (2010) Z. Wang et al. DIABETES CARE
- Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes
- (2010) S M Ocheltree et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes
- (2010) S. Arnolds et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Cost-effectiveness of insulin analogues for diabetes mellitus
- (2009) C. G. Cameron et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis
- (2009) S. R. Singh et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- Comparison of insulin detemir and insulin glargine in a basal—bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: A 52-week, multinational, randomized, open-label, parallel-group, Treat-to-Target noninferiority trial
- (2009) Simon Heller et al. CLINICAL THERAPEUTICS
- Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes
- (2009) Philip Raskin et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes
- (2008) Priscilla Hollander et al. CLINICAL THERAPEUTICS
- The Barrier of Hypoglycemia in Diabetes
- (2008) P. E. Cryer DIABETES
- The interpretation of glucose clamp studies of long-acting insulin analogues: from physiology to marketing and back
- (2008) S. G. H. A. Swinnen et al. DIABETOLOGIA
- A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes
- (2008) J. Rosenstock et al. DIABETOLOGIA
- 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
- (2008) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Superiority of insulin analogues versus human insulin in the treatment of diabetes mellitus
- (2008) Paolo Rossetti et al. ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started